| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,632,000 |
| Market
Cap: |
1.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$24.98 - $24.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Provention Bio is a biopharmaceutical company. Co.'s pipeline of investigational candidates under development includes: PRV-031 (teplizumab), an anti-CD3 monoclonal antibody (mAb) for the delay of clinical Type 1 Diabetes (T1D); PRV-3279, a bispecific scaffold molecule targeting the B-cell surface proteins, FcgammaRIIb and CD79B, for the treatment of systemic lupus erythematosus; PRV-015 (ordesekimab), an anti-interleukin 15 mAb for the treatment of gluten-free diet non-responsive celiac disease; and PRV-101, a Coxsackie Virus B (CVB) vaccine to prevent acute CVB infections and to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
5,594,666 |
| Total Sell Value |
$0 |
$0 |
$0 |
$85,590,128 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
13 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Leon Francisco |
Chief Scientific Officer |
• – – |
2023-01-18 |
4 |
AS |
$10.27 |
$246,584 |
D/D |
(24,015) |
1,573,000 |
|
177% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2023-01-18 |
4 |
OE |
$2.50 |
$60,038 |
D/D |
24,015 |
1,597,015 |
|
- |
|
| Palmer Ashleigh |
Director and CEO |
• • – |
2023-01-18 |
4 |
AS |
$10.27 |
$248,063 |
D/D |
(24,165) |
2,570,050 |
|
177% |
|
| Palmer Ashleigh |
Director and CEO |
• • – |
2023-01-18 |
4 |
OE |
$2.50 |
$60,413 |
D/D |
24,165 |
2,594,215 |
|
- |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-29 |
4 |
S |
$10.26 |
$1,918,601 |
D/D |
(187,000) |
1,573,000 |
|
-140% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-29 |
4 |
OE |
$2.50 |
$467,500 |
D/D |
187,000 |
1,760,000 |
|
- |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-27 |
4 |
S |
$10.00 |
$106,740 |
D/D |
(10,674) |
1,573,000 |
|
-155% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-27 |
4 |
OE |
$2.50 |
$26,685 |
D/D |
10,674 |
1,583,674 |
|
- |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-23 |
4 |
S |
$10.00 |
$3,750 |
D/D |
(375) |
1,573,000 |
|
-160% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-23 |
4 |
OE |
$2.50 |
$938 |
D/D |
375 |
1,573,375 |
|
- |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-22 |
4 |
S |
$10.00 |
$15,681 |
D/D |
(1,568) |
1,573,000 |
|
-151% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2022-12-22 |
4 |
OE |
$2.50 |
$3,920 |
D/D |
1,568 |
1,574,568 |
|
- |
|
| Petry John |
10% Owner |
– – • |
2022-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,879,023 |
|
107% |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2021-12-03 |
4 |
B |
$6.49 |
$33,765 |
D/D |
5,201 |
70,000 |
2.74 |
0% |
|
| Drechsler Andrew T |
Chief Financial Officer |
• – – |
2020-09-02 |
4 |
B |
$11.72 |
$23,440 |
D/D |
2,000 |
20,000 |
2.74 |
28% |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2020-09-02 |
4 |
B |
$12.06 |
$3,606 |
D/D |
299 |
64,799 |
2.66 |
28% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2020-08-21 |
4 |
B |
$13.35 |
$26,708 |
D/D |
2,000 |
2,567,450 |
2.74 |
29% |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2020-08-20 |
4 |
B |
$13.23 |
$33,075 |
D/D |
2,500 |
64,500 |
2.74 |
33% |
|
| Palmer Ashleigh |
President and CEO |
• • – |
2020-08-18 |
4 |
B |
$12.69 |
$6,345 |
D/D |
500 |
2,566,300 |
2.81 |
31% |
|
| Palmer Ashleigh |
President and CEO |
• • – |
2020-08-17 |
4 |
B |
$12.83 |
$35,924 |
D/D |
2,800 |
2,565,800 |
2.81 |
34% |
|
| Drechsler Andrew T |
Chief Financial Officer |
• – – |
2020-08-13 |
4 |
B |
$13.01 |
$22,768 |
D/D |
1,750 |
18,000 |
2.74 |
36% |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2020-06-24 |
4 |
B |
$15.43 |
$30,862 |
D/D |
2,000 |
2,565,450 |
2.74 |
-7% |
|
| Bluestone Jeffrey |
Director |
– • – |
2020-04-10 |
4 |
OE |
$2.36 |
$76,101 |
I/I |
32,246 |
39,571 |
|
- |
|
| Leon Francisco |
Chief Scientific Officer |
• – – |
2020-03-19 |
4 |
B |
$5.92 |
$59,200 |
D/D |
10,000 |
2,563,450 |
2.74 |
65% |
|
| Hoitt Jason |
Chief Commercial Officer |
• – – |
2020-03-19 |
4 |
B |
$5.43 |
$24,435 |
D/D |
4,500 |
4,500 |
2.74 |
65% |
|
94 Records found
|
|
Page 2 of 4 |
|
|
